What this study is
This cohort study will examine the clinical utility of genomic sequencing (GS) in patients undergoing prenatal diagnostic procedures (chorionic villus sampling or amniocentesis) for routine indications other than a structural fetal anomaly.
What's being tested
- Genomic Sequencing
Intervention · DEVICE
Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
Study details
- Sponsor
- University of California, San Francisco
- Conditions
- Pregnant Individuals Requesting Standard Microarray
- Enrolling
- 1,000 people
- Starts
- 2024-01-01
- Est. completion
- 2030-01
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 64 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Pregnant with a structurally normal fetus (singleton or multiple gestation)
- Planning to undergo prenatal diagnosis by either chorionic villus sampling or amniocentesis with chromosome microarray analysis for routine indications
- Planning, or have already completed expanded carrier screening
You can't join if
- Decline prenatal diagnostic testing
- Are pregnant and their fetus has a known anomaly
- Declined chromosomal microarray analysis of expanded carrier screening
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of California, San Francisco
San Francisco, California, United States
- Nuriye Sahin Hodoglugil, DrPH · ContactNuriye.Sahin-Hodoglugil@ucsf.edu
- Mary Norton, MD · Principal investigator
Recruiting
Study team
Sponsor
University of California, San Francisco
Study ID 23-38946
Principal investigator
Mary Norton, MD
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.